Big Pharma poured billions into AI drug discovery. It could soon pay off

ByCatherine Arnst

Eli Lilly is eyeing an off-ramp for patients to switch from weight loss injections to pills

ByCatherine Arnst

A federal panel picked by RFK Jr. voted to end Hepatitis B vaccines for newborns

ByCatherine Arnst

'There's never been a drug with this range': The weight loss boom is just getting started

ByCatherine Arnst

Ozempic is getting cheaper as Novo Nordisk rushes to undercut Eli Lilly

ByCatherine Arnst

Ozempic is coming to Thanksgiving

ByCatherine Arnst

1 in 5 U.S. adults say they've taken Ozempic or similar drugs, survey finds

ByCatherine Arnst

Eli Lilly and Novo Nordisk cut deals with Trump to lower weight loss drug prices

ByCatherine Arnst

Soaring drug prices are leaving inflation in the dust

ByCatherine Arnst

Trump says Ozempic will get much cheaper. Novo Nordisk and Eli Lilly shares tumble

ByCatherine Arnst

Wegovy and Zepbound should be the go-to obesity treatment, medical group says

ByCatherine Arnst

Health insurers say they'll keep covering vaccines as a political fight widens

ByCatherine Arnst

Trump's ongoing battle with the pharma industry shows no signs of easing

ByCatherine Arnst

RFK Jr. takes aim at court that protects vaccine makers from lawsuits

ByCatherine Arnst

WHO adds GLP-1 weight loss drugs to list of the world's essential medicines for the first time

ByCatherine Arnst

Corporate healthcare costs could soon see their biggest increase in a decade

ByCatherine Arnst

FDA biologics chief back 12 days after resigning, creating pressure on biotech stocks

ByCatherine Arnst

Eli Lilly and Novo Nordisk whipsawed by Wall Street's ever-rising hopes for weight loss drugs

ByCatherine Arnst

Novo Nordisk posts disappointing earnings as fierce Ozempic competition hits hard

ByCatherine Arnst

Turmoil at the FDA means uncertainty for innovative new drugs

ByCatherine Arnst

More stories